Literature DB >> 12117457

Fixed low-dose combination therapy for hypertension.

Bernard Waeber1.   

Abstract

Despite the availability of various classes of antihypertensive agents that lower blood pressure by different primary actions, the treatment of hypertension remains a difficult task. Essential hypertension has a highly heterogeneous character, so that monotherapies are often not sufficient to normalize blood pressure. This is especially true since the goal of treatment is currently to normalize both systolic and diastolic blood pressure. By combining medications acting by different mechanisms, it is possible to gain considerably in terms of antihypertensive efficacy because of synergistic impacts on the cardiovascular system. Furthermore, low doses of antihypertensive agents are generally sufficient when used in combination, which accounts for the excellent tolerability of combination products. Fixed low-dose combinations are very useful tools for treating hypertensive patients. Because of their simplicity of use, and the fact that they improve the blood pressure response rate while minimizing the incidence of adverse effects, such combinations are increasingly being considered as suitable for both second-line and first-line therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117457     DOI: 10.1007/s11906-996-0008-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  46 in total

1.  Low-dose combination therapy: an important first-line treatment in the management of hypertension.

Authors:  J M Neutel; D H Smith; M A Weber
Journal:  Am J Hypertens       Date:  2001-03       Impact factor: 2.689

2.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

3.  Evidence-based health policy--lessons from the Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

4.  Combination products as first-line pharmacotherapy.

Authors:  R R Fenichel; R J Lipicky
Journal:  Arch Intern Med       Date:  1994-07-11

5.  Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group.

Authors:  A H Gradman; N R Cutler; P J Davis; J A Robbins; R J Weiss; B C Wood
Journal:  Am J Cardiol       Date:  1997-02-15       Impact factor: 2.778

6.  Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients.

Authors:  M H Weinberger
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

7.  Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy.

Authors:  E Ambrosioni; G Leonetti; A C Pessina; A Rappelli; B Trimarco; A Zanchetti
Journal:  J Hypertens       Date:  2000-11       Impact factor: 4.844

8.  Optimisation of antihypertensive treatment by crossover rotation of four major classes.

Authors:  J E Dickerson; A D Hingorani; M J Ashby; C R Palmer; M J Brown
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

Review 9.  Angiotensin II receptor antagonists.

Authors:  M Burnier; H R Brunner
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

10.  Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine.

Authors:  S Attwood; R Bird; K Burch; B Casadei; A Coats; J Conway; M Dawes; D Ebbs; A Farmer; J Robinson
Journal:  J Hypertens       Date:  1994-09       Impact factor: 4.844

View more
  2 in total

Review 1.  Treating stage 2 hypertension.

Authors:  Thomas D Giles; Barry J Materson
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-08       Impact factor: 3.738

2.  Relaxation of rat aorta by farrerol correlates with potency to reduce intracellular calcium of VSMCs.

Authors:  Xiaojiang Qin; Xiaomin Hou; Mingsheng Zhang; Taigang Liang; Jianmin Zhi; Lingge Han; Qingshan Li
Journal:  Int J Mol Sci       Date:  2014-04-17       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.